Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

National Transportation Safety Board (NTSB) chair Jennifer Homendy provides an update Friday into the investigation of the ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, expectations were $-2.86. Operator: Good day, and thank you for standing ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised, ...

Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $39 from $38 and keeps an Equal Weight rating on the shares. The company’s ...

Canaccord Genuity upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...